| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2022-03-07 02:49:10 UTC |
|---|
| HMDB ID | HMDB0001509 |
|---|
| Secondary Accession Numbers | - HMDB0005092
- HMDB01509
- HMDB05092
|
|---|
| Metabolite Identification |
|---|
| Common Name | 20-Hydroxy-leukotriene B4 |
|---|
| Description | 20-hydroxy- Leukotriene B4 (20-OH-LTB4) is an omega-hydroxylated metabolite of leukotriene B4 in human neutrophils. Elevated urinary concentrations of 20-OH-LTB4 and LTB4 are found in patients with Sjogren-Larsson syndrome (SLS, OMIM 270220 ), an autosomal recessively inherited neurocutaneous disorder caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH), which as an essential role in LTB4 metabolism. Preterm birth seems to be one of the features of the syndrome. The reason for the preterm birth is unclear. It is hypothesized that it relates to the defective LTB4 degradation in SLS. The pathological urinary excretion of LTB4 and 20-OH-LTB4 is a biochemical marker for SLS. Surprisingly, 20-OH-LTB4 concentrations are normal in CSF. Leukotriene B4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. Other specific pathways of leukotriene metabolism include the 12-hydroxydehydrogenase/ 15-oxo-prostaglandin-13-reductase that form a series of conjugated diene metabolites that have been observed to be excreted into human urine. Metabolism of LTC4 occurs by sequential peptide cleavage reactions involving a gamma-glutamyl transpeptidase that forms LTD4 (leukotriene D4) and a membrane-bound dipeptidase that converts LTD4 into LTE4 (leukotriene E4) before w-oxidation. These metabolic transformations of the primary leukotrienes are critical for termination of their biological activity, and defects in expression of participating enzymes may be involved in specific genetic disease. (PMID: 12709426 , 9799565 , 11408337 , 17623009 ). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
|---|
| Structure | OCCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O InChI=1S/C20H32O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,18-19,21-23H,1-2,6,10-12,15-17H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9-/t18-,19-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoate | ChEBI | | (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate | ChEBI | | 20-Hydroxy-LTB4 | ChEBI | | 20-OH-Leukotriene b4 | ChEBI | | 20-OH-LTB4 | ChEBI | | (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoic acid | Generator | | (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoic acid | Generator | | (5S,12R)-5,12,20-Trihydroxy-(6Z,8E,10E,14Z)-eicosatetraenoate | HMDB | | (5S,12R)-5,12,20-Trihydroxy-(6Z,8E,10E,14Z)-eicosatetraenoic acid | HMDB | | (5S,6Z,8E,10E,12R,14Z)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate | HMDB | | (5S,6Z,8E,10E,12R,14Z)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoic acid | HMDB | | 20-Hydroxy LTB4 | HMDB | | 20-Hydroxyleukotriene b4 | HMDB | | 20-OH-5S,12S-Dihydroxy-6,10-trans-8,14-cis-eicosatetraenoate | HMDB | | 20-OH-5S,12S-Dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid | HMDB | | 5,12,20-THETE | HMDB | | 5,12,20-TriHETE | HMDB | | 5S,12R,20-Trihydroxy-6Z,8E,10E,14Z-eicosatetraenoate | HMDB | | 5S,12R,20-Trihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid | HMDB | | Omega-hydroxy-LTB4 | HMDB | | W-Hydroxy-LTB4 | HMDB | | [S-[R*,s*-(e,Z,e,Z)]]-5,12,20-trihydroxy-6,8,10,14-eicosatetraenoate | HMDB | | [S-[R*,s*-(e,Z,e,Z)]]-5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid | HMDB | | 20-Hydroxy-leukotriene b | HMDB | | 5,12,20-Trihydroxy-6,8,10,14-eicosatetraenoic acid | HMDB | | 5,12,20-Trihydroxy-6,8,10,14-eicosatetraenoic acid, (S-(r*,s*-(e,Z,e,Z)))-isomer | HMDB |
|
|---|
| Chemical Formula | C20H32O5 |
|---|
| Average Molecular Weight | 352.4651 |
|---|
| Monoisotopic Molecular Weight | 352.224974134 |
|---|
| IUPAC Name | (5S,6Z,8E,10E,12R,14Z)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid |
|---|
| Traditional Name | 20-hydroxy-LTB4 |
|---|
| CAS Registry Number | 79516-82-8 |
|---|
| SMILES | OCCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H32O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,18-19,21-23H,1-2,6,10-12,15-17H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9-/t18-,19-/m1/s1 |
|---|
| InChI Key | PTJFJXLGRSTECQ-PSPARDEHSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as leukotrienes. These are eicosanoids containing a hydroxyl group attached to the aliphatic chain of an arachidonic acid. Leukotrienes have four double bonds, three (and only three) of which are conjugated. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Leukotrienes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Leukotriene
- Hydroxyeicosatetraenoic acid
- Long-chain fatty acid
- Hydroxy fatty acid
- Fatty acid
- Unsaturated fatty acid
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Polyol
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Primary alcohol
- Carbonyl group
- Organooxygen compound
- Alcohol
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Liquid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.37 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.0292 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.77 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 62.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2564.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 219.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 162.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 182.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 229.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 544.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 400.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 191.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1285.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 498.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1220.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 405.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 376.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 405.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 187.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 20-Hydroxy-leukotriene B4,1TMS,isomer #1 | C[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O | 3269.3 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TMS,isomer #2 | C[Si](C)(C)O[C@@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O)C/C=C\CCCCCO | 3260.7 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TMS,isomer #3 | C[Si](C)(C)O[C@H](/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO)CCCC(=O)O | 3254.2 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TMS,isomer #4 | C[Si](C)(C)OC(=O)CCC[C@H](O)/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO | 3171.5 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #1 | C[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O)O[Si](C)(C)C | 3329.8 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #2 | C[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@H](CCCC(=O)O)O[Si](C)(C)C | 3316.7 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #3 | C[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O[Si](C)(C)C | 3225.1 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #4 | C[Si](C)(C)O[C@H](/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C)CCCC(=O)O | 3314.8 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #5 | C[Si](C)(C)OC(=O)CCC[C@H](O)/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C | 3234.1 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TMS,isomer #6 | C[Si](C)(C)OC(=O)CCC[C@@H](/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO)O[Si](C)(C)C | 3220.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TMS,isomer #1 | C[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@H](CCCC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 3323.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TMS,isomer #2 | C[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3237.5 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TMS,isomer #3 | C[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3223.2 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TMS,isomer #4 | C[Si](C)(C)OC(=O)CCC[C@@H](/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C)O[Si](C)(C)C | 3256.0 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,4TMS,isomer #1 | C[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 3244.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O | 3518.4 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O)C/C=C\CCCCCO | 3497.3 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@H](/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO)CCCC(=O)O | 3491.7 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)CCC[C@H](O)/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO | 3418.7 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3803.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3792.6 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C | 3713.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@H](/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C(C)(C)C)CCCC(=O)O | 3776.8 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)CCC[C@H](O)/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C(C)(C)C | 3713.9 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,2TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)OC(=O)CCC[C@@H](/C=C\C=C\C=C\[C@H](O)C/C=C\CCCCCO)O[Si](C)(C)C(C)(C)C | 3705.3 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4059.2 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3999.6 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3987.5 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)CCC[C@@H](/C=C\C=C\C=C\[C@@H](C/C=C\CCCCCO)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3992.2 | Semi standard non polar | 33892256 | | 20-Hydroxy-leukotriene B4,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCCC/C=C\C[C@H](/C=C/C=C/C=C\[C@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4241.5 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Berry KA, Borgeat P, Gosselin J, Flamand L, Murphy RC: Urinary metabolites of leukotriene B4 in the human subject. J Biol Chem. 2003 Jul 4;278(27):24449-60. Epub 2003 Apr 22. [PubMed:12709426 ]
- Willemsen MA, Rotteveel JJ, de Jong JG, Wanders RJ, IJlst L, Hoffmann GF, Mayatepek E: Defective metabolism of leukotriene B4 in the Sjogren-Larsson syndrome. J Neurol Sci. 2001 Jan 15;183(1):61-7. [PubMed:11166796 ]
- Goldman DW, Olson DM, Payan DG, Gifford LA, Goetzl EJ: Development of receptors for leukotriene B4 on HL-60 cells induced to differentiate by 1 alpha,25-dihydroxyvitamin D3. J Immunol. 1986 Jun 15;136(12):4631-6. [PubMed:3011899 ]
- Willemsen MA, IJlst L, Steijlen PM, Rotteveel JJ, de Jong JG, van Domburg PH, Mayatepek E, Gabreels FJ, Wanders RJ: Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome. Brain. 2001 Jul;124(Pt 7):1426-37. [PubMed:11408337 ]
- Murphy RC, Gijon MA: Biosynthesis and metabolism of leukotrienes. Biochem J. 2007 Aug 1;405(3):379-95. [PubMed:17623009 ]
- Jin R, Koop DR, Raucy JL, Lasker JM: Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Arch Biochem Biophys. 1998 Nov 1;359(1):89-98. [PubMed:9799565 ]
|
|---|